FORT MILL, SC / ACCESSWIRE / April 17, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., participates in the European Heart Rhythm Association (EHRA). EHRA will take place in Barcelona, Spain from April 16-18. As a branch of the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA) is the leading network of European Cardiac Rhythm Management. The EHRA is a strong association with more than 4,100 members around the globe, including physicians, arrhythmologists, young electrophysiologists, nurses and allied professionals.
David Jenkins, CEO of Ra Medical Systems, said, "The acceptance of clinical science provides an opportunity for the EP community to come together and discuss ways to improve treatment of cardiac arrhythmias. Multiple abstracts from leading physicians is indicative of the important roll VIVO has in aiding ventricular ablations and signals clinical acceptance and adoption of VIVO among the community."
As previously announced, multiple submissions about Catheter Precision's VIVO system were accepted and will be presented at 2023 conference:
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Ra Medical Systems
Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
CONTACTS:
At the Company
David Jenkins
973-691-2000
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.46 |
Daily Change: | 0.03 7.12 |
Daily Volume: | 70,750 |
Market Cap: | US$455K |
August 06, 2024 January 02, 2024 December 22, 2023 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB